TG Therapeutics' BRIUMVI Shows Sustained Efficacy and Safety in Five-Year MS Study

Event summary

  • Five-year data from the ULTIMATE I and II trials show BRIUMVI's annualized relapse rate dropped to 0.020 by year 5, equivalent to one relapse every 50 years of treatment.
  • Over 70% of participants remained on BRIUMVI treatment at year 5, highlighting strong long-term tolerability.
  • The study, published in JAMA Neurology, involved over 3,600 participant-years of ublituximab exposure.
  • BRIUMVI demonstrated a consistent safety profile with no new safety signals emerging over five years.

The big picture

TG Therapeutics' long-term data for BRIUMVI reinforces its position in the relapsing MS treatment landscape, where high-efficacy therapies are increasingly prioritized for early intervention. The sustained efficacy and safety profile could bolster its competitive edge against established treatments like ocrelizumab and ofatumumab. The results also underscore the growing emphasis on long-term evidence in autoimmune disease management, a trend that may influence future treatment guidelines and payer coverage decisions.

What we're watching

Market Positioning
Whether BRIUMVI can sustain its role as a high-efficacy therapy in the competitive relapsing MS market.
Regulatory Dynamics
The pace at which regulatory approvals expand for BRIUMVI in international markets.
Commercial Execution
How TG Therapeutics leverages these long-term data to drive physician and patient adoption.